FAP
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
RNA Therapeutic
2100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Ionis PharmaceuticalsCARLSBAD, CA
2 programs1
1
InotersenPhase 3RNA Therapeutic1 trial
InotersenPhase 2/3RNA Therapeutic1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Ionis PharmaceuticalsInotersen
Ionis PharmaceuticalsInotersen
Philogen[177Lu]Lu-OncoFAP-23
Clinical Trials (3)
Total enrollment: 364 patients across 3 trials
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Start: Jun 2014Est. completion: Jan 2021135 patients
Phase 3Completed
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
Start: Mar 2013Est. completion: Nov 2017173 patients
Phase 2/3Completed
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Start: Oct 2025Est. completion: Dec 202856 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 364 patients
RNA Therapeutic is the dominant modality (100% of programs)
2 companies competing in this space